Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
QuintilesIMS
Federal Trade Commission
Chubb
Deloitte
Teva
AstraZeneca
Argus Health
Merck

Generated: January 18, 2018

DrugPatentWatch Database Preview

Shionogi Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SHIONOGI INC, and what generic alternatives to SHIONOGI INC drugs are available?

SHIONOGI INC has six approved drugs.

There are nine US patents protecting SHIONOGI INC drugs on SHIONOGI INC drugs in the past three years.

There are eighty-two patent family members on SHIONOGI INC drugs in twenty-five countries and fourteen supplementary protection certificates in seven countries.

Summary for Shionogi Inc
International Patents:82
US Patents:9
Tradenames:6
Ingredients:6
NDAs:6

Drugs and US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 ➤ Subscribe ➤ Subscribe
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-003 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SHIONOGI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Lotion 5% ➤ Subscribe 4/11/2016
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 10/11/2011

Non-Orange Book US Patents for Shionogi Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,084,460 6,7-unsaturated-7-carbamoyl substituted morphinan derivative ➤ Subscribe
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Subscribe
9,296,756 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Subscribe
8,536,192 6,7-unsaturated-7-carbamoyl substituted morphinan derivative ➤ Subscribe
9,464,094 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Subscribe
9,315,512 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Shionogi Inc Drugs

Supplementary Protection Certificates for Shionogi Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3 Finland ➤ Subscribe
C/GB12/030 United Kingdom ➤ Subscribe PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
C0005 France ➤ Subscribe PRODUCT NAME: DORIPENEME; REGISTRATION NO/DATE IN FRANCE: EU/1/07/467/001 DU 20080725; REGISTRATION NO/DATE AT EEC: EU/1/08/467/001 DU 20080725
C/GB09/006 United Kingdom ➤ Subscribe PRODUCT NAME: DORIPENEM; REGISTERED: UK EU/1/08/467/001 20080725
00133 Netherlands ➤ Subscribe PRODUCT NAME: OLMESARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN DE CARBOXYGROEP GEKOZEN UIT DE VOLGENDE : EEN ALKYLGROEP 1-4 KOOLSTOFATOMEN, EEN BENZYLGROEP, EEN ALKANOYLOXYALKYLGROEP WAARIN HET ALKANOYLDEEL 1-5; NATL. REGISTRATION NO/DATE: RVG 28785-RVG 28787 20030527; FIRST REGISTRATION: DE 502.02.00.00,502.02.01.00, 502.02.02.00 20020813
2009 00003 Denmark ➤ Subscribe PRODUCT NAME: DORIPENEM, HERUNDER DORIPENEMMONOHYDRAT; REG. NO/DATE: EU/1/08/467/001 20080725
C/GB04/012 United Kingdom ➤ Subscribe PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
C/GB01/002 United Kingdom ➤ Subscribe PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
C0041 France ➤ Subscribe PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
09/002 Ireland ➤ Subscribe PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Accenture
US Department of Justice
Chubb
Harvard Business School
Fish and Richardson
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot